Rhythm Pharmaceuticals, Inc. (RYTM)
92.83
-0.58
(-0.62%)
USD |
NASDAQ |
Oct 02, 16:00
92.86
+0.02
(+0.03%)
After-Hours: 20:00
Rhythm Pharmaceuticals Enterprise Value : 6.281B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 6.281B |
| October 01, 2026 | 6.321B |
| September 30, 2026 | 6.446B |
| September 29, 2026 | 6.480B |
| September 28, 2026 | 6.676B |
| September 25, 2026 | 6.683B |
| September 24, 2026 | 6.659B |
| September 23, 2026 | 6.654B |
| September 22, 2026 | 6.725B |
| September 21, 2026 | 6.694B |
| September 18, 2026 | 6.617B |
| September 17, 2026 | 6.707B |
| September 16, 2026 | 6.638B |
| September 15, 2026 | 6.553B |
| September 14, 2026 | 6.943B |
| September 11, 2026 | 7.099B |
| September 10, 2026 | 6.926B |
| September 09, 2026 | 6.848B |
| September 08, 2026 | 6.899B |
| September 04, 2026 | 6.963B |
| September 03, 2026 | 7.111B |
| September 02, 2026 | 7.148B |
| September 01, 2026 | 7.101B |
| August 31, 2026 | 7.197B |
| August 28, 2026 | 7.268B |
| Date | Value |
|---|---|
| August 27, 2026 | 7.637B |
| August 26, 2026 | 7.592B |
| August 25, 2026 | 7.694B |
| August 24, 2026 | 7.562B |
| August 21, 2026 | 7.463B |
| August 20, 2026 | 7.389B |
| August 19, 2026 | 7.857B |
| August 18, 2026 | 7.824B |
| August 17, 2026 | 7.837B |
| August 14, 2026 | 7.840B |
| August 13, 2026 | 7.877B |
| August 12, 2026 | 7.986B |
| August 11, 2026 | 7.659B |
| August 10, 2026 | 7.840B |
| August 07, 2026 | 7.851B |
| August 06, 2026 | 7.608B |
| August 05, 2026 | 7.512B |
| August 04, 2026 | 7.173B |
| August 03, 2026 | 6.966B |
| July 31, 2026 | 6.723B |
| July 30, 2026 | 7.170B |
| July 29, 2026 | 7.224B |
| July 28, 2026 | 7.328B |
| July 27, 2026 | 7.197B |
| July 24, 2026 | 6.919B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| BioMarin Pharmaceutical, Inc. | 14.41B |
| Cytokinetics, Inc. | 9.205B |
| Exelixis, Inc. | 13.86B |
| Ionis Pharmaceuticals, Inc. | 7.346B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -49.30M |
| Revenue (Quarterly) | 71.26M |
| Total Expenses (Quarterly) | 120.55M |
| EPS Diluted (Quarterly) | -0.7342 |
| Gross Profit Margin (Quarterly) | 87.39% |
| Profit Margin (Quarterly) | -69.19% |
| Earnings Yield | -3.36% |
| Normalized Earnings Yield | -3.348 |